Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kai Li has a total of 197 co-authors. Here are the top co-authors by number of shared publications:

  • Jing Wang

    Department of Thoracic Oncology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    17 shared publications
  • Xinyue Wang

    Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    12 shared publications
  • Cuicui Zhang

    Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    10 shared publications
  • Zhujun Liu

    National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    10 shared publications
  • Tingting Qin

    Department of Thoracic Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, China

    9 shared publications
  • Baohui Han

    Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    8 shared publications

Latest Publications

  • Top Cited Papers

    Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial

    by Hua Zhong, Jing Wang, Runxiang Yang, Yongzhong Luo, Wei Zuo, Wei Zhang, Chao Xie, Qingshan Li, Qiang Liu, Xingxiang Xu, et al.


  • Open Access

    PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib

    by Yingfang Feng, Yuan Gao, Shaochuan Liu, Tingting Qin, Yan Zhang, Jing Wang, Kai Li

    Background: Immunotherapy plays a crucial role in the treatment of tumors. However, few studies have investigated the relationship between the expression of Programmed Cell Death Ligand 1 (PD-L1, CD274) in microvascular endothelial cells (MECs), including blood endothelial cells (BECs) and lymphatic endothelial cells (LECs), and immune cell infiltration within tissues.Methods: In our study, we utilized data from The Cancer Genome Atlas, a mouse subcutaneous xenograft model, and immunofluorescence and immunohistochemical staining to investigate the relationship between PD-L1 expression in melanoma MECs at different tumor stages and the infiltration of CD8+ T cells in tumor and normal organs, under conditions with and without anlotinib treatment.Results: We found that PD-L1 expression was upregulated in tumor MECs, while anlotinib downregulated PD-L1 expression in both tumor and normal tissue MECs, corresponding with increased infiltration of CD8+ T cells in the tissues. Additionally, the antitumor effect of anlotinib was most pronounced when administered during the mid-stage of tumor development.Conclusions: This study evaluated the most effective timing for anlotinib to downregulate PD-L1 expression in tumor and normal tissues to promote immune infiltration. Our findings may offer valuable insights for the clinical use of anlotinib and its potential side effects.

  • Open Access

    Correlation of inflammatory markers with progression-free survival in advanced lung cancer patients treated with immune checkpoint inhibitors in combination with chemotherapy: a real-world study

    by Shijun Li, Cuicui Zhang, Xinyue Wang, Jing Wang, Kai Li

    Immune checkpoint inhibitors (ICIs), principally represented by programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors have been used in the first-line treatment of advanced lung cancer by Chinese Society of Clinical Oncology (CSCO) since 2018. Biomarkers like PD-L1 and tumor mutational burden (TMB) help to differentiate patients who benefited from ICI therapy. This study aimed to confirm and assess the predictive value of inflammatory markers in advanced lung cancer patients with the treatment of ICIs plus chemotherapy in the real world. The parameters of patients were collected in this retrospective study. Inflammatory markers were mainly calculated at different treatment periods. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated with the univariate and multivariate Cox proportional hazard model. The Cox multivariate regression analysis indicated that a higher eosinophil-to-lymphocyte ratio (ELR) (HR 0.399, 95% CI: 0.189–0.842, P=0.02) and a higher monocyte-to-lymphocyte ratio (MLR) (HR 2.162, 95% CI: 1.116–4.191, P=0.02) at the time of maximizing therapeutic benefits, a higher lactate dehydrogenase (LDH) (HR 2.456, 95% CI: 1.334–4.523, P=0.004) at the time of disease progression were independent risk factors. A higher ELR and a lower MLR at maximizing therapeutic benefits and a lower LDH at disease progression were positive protectors for the progression-free survival (PFS) of advanced lung cancer treated with ICI combined with platinum-based chemotherapy.


  • Open Access

    Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial

    by Cuicui Zhang, Tianqing Chu, Qiming Wang, Ying Cheng, Yongxiang Zhang, Ruili Wang, Leilei Ma, Chaonan Qian, Baohui Han, Kai Li

    Objective: The possible enhancing effect of anlotinib on programmed death receptor ligand (PD-L1) antibody and the efficacy-predicting power of PD-L1 in micro-conduit endothelium, including lymphatic endothelial cells (LECs) and blood endothelial cells (BECs), were determined to identify patients who would benefit from this treatment. Methods: PD-L1 positivity in LECs, BECs, and tumor cells (TCs) was assessed using paraffin sections with multicolor immunofluorescence in an investigator’s brochure clinical trial of TQB2450 (PD-L1 antibody) alone or in combination with anlotinib in patients with non-small cell lung cancer. Progression-free survival (PFS) with different levels of PD-L1 expression was compared between the two groups. Results: Among 75 patients, the median PFS (mPFS) was longer in patients who received TQB2450 with anlotinib [10 and 12 mg (161 and 194 days, respectively)] than patients receiving TQB2450 alone (61 days) [hazard ratio (HR)10 mg = 0.390 (95% confidence interval {CI}, 0.201–0.756), P = 0.005; HR12 mg = 0.397 (0.208–0.756), P = 0.005]. The results were similar among 58 patients with high PD-L1 expression in LECs and TCs [159 and 209 vs. 82 days, HR10 mg = 0.445 (0.210–0.939), P = 0.034; HR12 mg = 0.369 (0.174–0.784), P = 0.009], and 53 patients with high PD-L1 expression in BECs and TCs [161 and 209 vs. 41 days, HR10 mg = 0.340 (0.156–0.742), P = 0.007; HR12 mg = 0.340 (0.159–0.727), P = 0.005]. No differences were detected in the mPFS between the TQB2450 and combination therapy groups in 13 low/no LEC-expressing and 18 low/no BEC-expressing PD-L1 cases. Conclusions: Mono-immunotherapy is not effective in patients with high PD-L1 expression in LECs and/or BECs. Anlotinib may increase efficacy by downregulating PD-L1 expression in LECs and/or BECs, which is presumed to be a feasible marker for screening the optimal immune patient population undergoing anti-angiogenic therapy.


  • Open Access

    A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer

    by Wei Zhang, Jing Wang, Qiming Wang, Ying Cheng, Lei Yang, Yuechuan Li, Hua Zhong, Tianqing Chu, Yu Dong, Yanwei Zhang, et al.


  • Open Access

    Changes in PD-L1 expression on microvessel endothelial cells during melanoma tumor growth and the regulation by anlotinib

    by Yingfang Feng, Yuan Gao, Tingting Qin, Yan Zhang, Shaochuan Liu, Jing Wang, Kai Li

    To evaluate the expression of PD-L1 on MEC in tumor and normal tissues, IF was used to detect the expression of PD-L1+CD31+ VECs and PD-L1+ Podoplanin + LECs in tumor, ear and kidney tissues. We found that the MEC PD-L1 in tumor showed an upward trend with tumor progression. The expression of PD-L1 in MEC in normal tissues is associated with the type of microvessels and tumor progression. The MEC PD-L1 expression in tumor is significantly down-regulated at 22th day in An5-9 group. In the early treatment group (An5-9), anlotinib increased the LEC PD-L1 but had no significant effect on VEC PD-L1 of ear, while decreased the LEC PD-L1 in kidney. In conclusion, the MEC-PD-L1 in melanoma increased with tumor growth and was downregulated significantly by early treatment of anlotinib, which proposes a potentiality of its enhancement on the therapeutic efficacy of anti-PD-L1 antibody. Anlotinib had no significant effect on the MEC PD-L1 of ear excepting the upregulation of LEC PD-L1 in early treatment group, while decreased such expression in kidney, hence the risk of possible renal damage by CD8 + T cells in the treatment of anlotinib should be bewared.

  • Open Access

    Immune‐independent acquired resistance to PD‐L1 antibody initiated by PD‐L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib

    by Yuan Gao, Yingfang Feng, Shaochuan Liu, Yan Zhang, Jing Wang, Tingting Qin, Peng Chen, Kai Li

    Despite the benefit with cancer immunotherapies in clinical implication, immunotherapeutic resistance occurred in many patients and the mechanism remains unknown. Increasing evidence has revealed that cell‐intrinsic programmed cell death ligand 1 (PD‐L1) may play a non‐negotiable part in immunotherapeutic resistance. Our present study aimed to elucidate the immune‐independent acquired resistance mechanism to PD‐L1 antibody. We found elevated PD‐L1 expression induced by PD‐L1 antibodies in cancer cell and vascular endothelial cells (VECs) with substantially acquired resistance to PD‐L1 antibodies. Moreover, proliferation of resistant cells was accelerated and the apoptosis was reduced in the absence of immune compared with parental cells. Subsequently, we confirmed that the activation of the PI3K/AKT pathway is involved in the upregulation of PD‐L1 expression. Finally, we found that low dose of anlotinib downregulated PD‐L1 expression only in VECs via inhibiting the PI3K/AKT pathway; however, the same effect was not observed in cancer cells. To sum up, our findings revealed that upregulation of PD‐L1 via activation of the PI3K/AKT signal pathway may promote acquired resistance to PD‐L1 antibodies in an immune‐independent manner.Significance: These findings provide new mechanisms of immunotherapeutic resistance and effective evidence of anlotinib combined with immunotherapy.


  • Open Access

    Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab

    by Zhujun Liu, Tingting Qin, Xiaohan Yuan, Jie Yang, Wei Shi, Xiaoling Zhang, Yanan Jia, Shaochuan Liu, Jing Wang, Kai Li

    Background: Bevacizumab is the representative drug in antiangiogenic therapy for lung cancer. However, it induced resistance in some neoplasm. Anlotinib, a novel multi-target tyrosine kinase inhibitor which has an inhibitory action on both angiogenesis and malignancy, is possible to reverse the resistance.Methods: Transwell migration and invasion experiments of bevacizumab with or without anlotinib were conducted to verify the activated/inhibited ability of lung adenocarcinoma cells. We sequenced A549 cells with enhanced migration and invasion abilities after bevacizumab treatment, screened out the differentially expressed gene and further confirmed by western blot and q-PCR assays. We also investigated immunohistochemical staining of tumor tissue in mice and human lung adenocarcinoma.Results: Bevacizumab facilitated migration and invasion of lung adenocarcinoma cells. Differentially expressed gene RGC32 was screened out. Bevacizumab upregulated the expression of RGC32, N-cadherin, and MMP2 through ERK-MAPK and PI3K-AKT pathways. Anlotinib downregulated their expression and reversed the effect of bevacizumab on A549 cells. In vivo experiments confirmed that higher-dose bevacizumab facilitated metastasis in tumor-bearing nude mice and upregulated the expression of RGC32, N-cadherin, and MMP2, whereas anlotinib abrogated its effect. Expression of both RGC32 and N-cadherin positively correlated with lymph node metastasis and stage in lung adenocarcinoma was found. Survival analysis revealed that higher expressions of RGC32 and N-cadherin were associated with poor progression-free survival and overall survival.Conclusions: Bevacizumab may promote invasion and metastasis of lung adenocarcinoma cells by upregulating RGC32 through ERK-MAPK and PI3K-AKT pathways to promote epithelial–mesenchymal transition, whereas anlotinib reverses the effect. RGC32 and N-cadherin are independent prognostic factors in lung adenocarcinoma.


  • Open Access

    The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study

    by Yizhuo Zhao, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Weiqiang Chen, Yi Luo, et al.

    Background: Anlotinib demonstrated improved overall survival (OS) and progression-free survival (PFS) compared with placebo as a third-line or subsequent therapy in patients with non-small cell lung cancer (NSCLC) in the ALTER0303 trial. The status of epidermal growth factor receptor (EGFR) mutation, different previous treatment may affect the efficacy of subsequent therapy, and we did this subgroup analysis to characterize the efficacy of anlotinib in patients with and without EGFR mutation. Methods: The ALTER0303 trial was a randomized, double-blind, phase 3 study of anlotinib in patients with NSCLC who failed at least 2 lines of treatment. In the study, 138 of 437 randomized patients were EGFR mutation positive. A Cox model was used to examine the influence of previous treatment on the efficacy of anlotinib according to EGFR mutation status. Results: For patients with EGFR mutation, the OS was 10.7 and 6.3 months (HR 0.59; 95% CI: 0.38–0.94, P=0.025) in the anlotinib and placebo group, respectively. The PFS was 5.6 and 0.8 months (HR 0.21; 95% CI: 0.13–0.32, PConclusions: This analysis demonstrated that the benefit of anlotinib as a third-line therapy for patients with NSCLC was independent of EGFR mutation status.


  • Open Access

    A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

    by Hai-Yan Tu, Jifeng Feng, Meiqi Shi, Jun Zhao, Yuyan Wang, Jianhua Chang, Jialei Wang, Ying Cheng, Jing Zhu, Eng-Huat Tan, et al.

    Background Afatinib has been shown as a suitable option for the treatment of epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) in randomized controlled trials. However, patients treated in real-world clinical practice, including elderly patients, and those with brain metastases or poor Eastern Cooperative Oncology Group (ECOG) performance statuses, are often excluded from these studies. Objective To report the final results, with a particular focus on patients enrolled in China, from a prospective phase IIIb, “near real-world” study of afatinib in tyrosine kinase inhibitor (TKI)-naïve Asian patients with EGFRm+ NSCLC. Patients and Methods NCT01953913 was conducted at 34 centers across Asia. Entry criteria were broad to reflect real-world settings. Patients received afatinib 40 mg/day until tumor progression, lack of clinical benefit, or poor tolerability. Assessments included safety, time to symptomatic progression (TTSP), and progression-free survival (PFS). Results 541 patients were treated, of whom 412 were enrolled in China. Dose reductions were implemented in 28.7% of patients overall, and 17.7% of patients from China. Safety findings were consistent with phase III studies of afatinib. Median TTSP in all patients was 14.0 months (95% CI 12.9–15.9), and median PFS was 12.1 months (95% CI 11.0–13.6). Median TTSP (13.8 months, 95% CI 12.7–16.1) and PFS (11.4 months, 95% CI 10.9–13.7) were similar in patients from China to the overall population. Among patients from China who had dose reductions, TTSP was numerically longer than in those who did not (16.4 vs. 13.8 months; P = 0.0703), while PFS was significantly longer (13.9 vs. 11.1 months; P = 0.0275). Among patients from China with brain metastases, TTSP was numerically shorter than in those without (11.0 vs. 14.4 months; P = 0.0869), whereas PFS was significantly shorter (9.2 vs. 12.9 months; P = 0.0075). Conclusions Safety data for afatinib when used in a “near real-world” setting in patients with EGFRm+ NSCLC was consistent with the known safety profile of afatinib. Supporting efficacy data of afatinib were provided in all patients, and in those enrolled in China. Tolerability-guided afatinib dose reduction allowed patients to remain on treatment and continue to experience clinical benefit. Trial Registration Number and Date of Registration NCT01953913 (1 October 2013).